Comparative Pharmacology
Head-to-head clinical analysis: DERMACORT versus DESONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMACORT versus DESONIDE.
DERMACORT vs DESONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Desonide is a synthetic corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators like cytokines, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin film to affected area twice daily (every 12 hours) for up to 2 weeks.
Topical: Apply a thin film to affected area 2-3 times daily; maximum 2 weeks of continuous therapy. Intralesional: Not applicable for desonide. Ophthalmic: Not indicated.
None Documented
None Documented
Clinical Note
moderateDesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateDesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Desonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Rosoxacin
Terminal elimination half-life is approximately 2-3 hours for hydrocortisone, the active component. Due to its short half-life, it requires multiple daily doses for sustained effect.
Terminal elimination half-life is 2-3 hours in adults, consistent with short glucocorticoid activity; prolonged in hepatic impairment.
Primarily hepatic metabolism; metabolites are excreted renally (~75% as glucuronide and sulfate conjugates) and fecally (~25%). Less than 5% of the dose is excreted unchanged in urine.
Renal (approximately 75% as metabolites, <10% unchanged); biliary/fecal (25%)
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."